blood disorders

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

Events

Partner Content

2nd Gene Therapy for Blood Disorders

Gene Therapy for Blood Disorders Digital Summit

News

Celgene files potential blockbuster luspatercept

Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up what could be a new blockbuster for the soon-to-be acquired Celgene.

Agios shares slump on sickle cell disease data

2nd Gene Therapy for Blood Disorders

Celgene files potential blockbuster luspatercept

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks